

Vaccine Research and Development Initiatives
National Institute of Allergy and Infectious Diseases

Note: This table describes unfunded vaccine research and development opportunities for supplemental funding in 1993 and for additional resources provided in FY 1994 and thereafter. These are not listed in priority order. projects for FY 1993 are defined by scientific goals as well as programmatic opportunities. As requested, the items described herein are focused primarily on research to accomplish three objectives defined as priorities for these resources:

1. To develop children's vaccines,
2. To improve vaccine safety, and
3. To develop vaccines for emerging infectious diseases.

Research Objective	Estimated First Year Cost	Initiatives	Category
Define Mechanisms of Pathogenesis	FY 93: \$1,750,000	Expand basic research on improved measles vaccines, including viral induced immunosuppression	R&D
		Expand research on safety of RSV vaccine candidates	Vaccine Safety R&D
	FY 94: \$3,500,000	Expand intramural research on children's vaccines Antibodies against internal proteins; Enhancing immune response in newborns; Modification of the varicella virus to create new vaccines	R&D
		Understand the molecular determinants of arthritis following rubella immunization, particularly in women	Vaccine Safety R&D
Define Mechanisms of Protective Immunity	FY 93: \$1,000,000	Improve the understanding of neonatal immunology	P & D
		Overcoming Issues of immunopotential in RSV vaccines	Vaccine Safety R&D
		Expand research on mucosal immunology	R&D
	FY 94: \$6,500,000	Expand basic research on tuberculosis vaccines	Emerging R&D
		Immunogenetic determinants of vaccine response and vaccine safety in U.S. populations	Vaccine Safety R&D